Agenus Inc. (AGEN)

Oncology Corporate Profile

Stock Performance

4.0200
0.0000

HQ Location

3 Forbes Road
Lexington, MA 02421

Company Description

Agenus Inc., a biotechnology company, develops and commercializes immunotherapies for cancer and infectious diseases. It markets Oncophage vaccine for the treatment of adjuvant renal cell carcinoma (kidney cancer). The company also has various product candidates under development, which include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of non-small cell lung cancer and melanoma.

Website: http://www.agenusbio.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Oncophage_ / vitespenimmunotherapy1st line metastatic MelanomaIII
Oncophage_ / vitespenimmunotherapy1st line metastatic Renal cell carcinoma (RCC)III
Oncophage_ / vitespenimmunotherapy2nd line metastatic GliomaII
Oncophage_ / vitespenimmunotherapyColorectal cancerII
Aroplatin_ / liposomal aroplatinliposomal platinum agentB-cell Non-Hodgkin's Lymphoma (NHL)I
Aroplatin_ / liposomal aroplatinliposomal platinum agentColorectal cancerI
Aroplatin_ / liposomal aroplatinliposomal platinum agentVarious cancer typesI
Oncophage_ / vitespenimmunotherapyGastric cancerI
Oncophage_ / vitespenimmunotherapyGlioblastoma Multiforme (GBM)I
Oncophage_ / vitespenimmunotherapyNon Small Cell Lung Cancer (NSCLC)I
Oncophage_ / vitespenimmunotherapyPancreatic cancerI
ATRA-IVliposomal retinoic acidMelanomaPreclinical
ATRA-IVliposomal retinoic acidRenal cell carcinoma (RCC)Preclinical

View additional information on product candidates here »

Pipeline image

Source


http://www.agenusbio.com

Recent News Headlines

Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors

6/22/2016 01:45 pm

(The Street) June 22, 2016 - Agenus Inc., an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that the first patient has been dosed in a Phase 1/2 clinical trial of the anti-GITR agonist antibody INCAGN1876. The trial is being conducted by, and in collaboration with, Incyte Corporation.

Agenus Commences Phase 1 Clinical Trial of its CTLA-4 Checkpoint Antibody to Treat Solid Tumors

4/27/2016 12:01 pm

(Agenus) Apr 27, 2016 - Agenus Inc., an immuno-oncology company developing checkpoint antibodies and cancer vaccines, today announced that the first patient has been dosed in the company’s Phase 1 clinical trial of AGEN1884, an anti-CTLA-4 checkpoint (CPM) antibody.

EBCC-10 NEWS: Full Dose Radiotherapy To Whole Breast May Not Be Needed In Early Breast Cancer: First Results Of Local Recurrence In Women Participating In the IMPORT LOW TRIAL

3/9/2016 11:01 am

(ECCO) Mar 9, 2016 - Radiotherapy to the whole breast is standard treatment after breast-conserving surgery for women with early breast cancer, even those who have a low risk of the disease returning in the breast (local relapse).

Agenus Announces Clearance of Investigational New Drug Applications by the FDA for anti-CTLA-4 and anti-GITR Antibodies

1/21/2016 12:08 pm

(StreetInsider) Jan 21, 2016 - Agenus Inc., an immuno-oncology company developing checkpoint modulator antibodies and cancer vaccines, announced today that the U.S. Food and Drug Administration (FDA) cleared the company's investigational new drug (IND) application for AGEN1884, an immune checkpoint modulator (CPM) antibody that binds to cytotoxic T-lymphocyte antigen-4 (CTLA-4).

Agenus Acquires Novel Antibodies to Immuno-oncology Target CEACAM1

7/21/2015 11:58 am

(MarketWatch) July 20, 2015 - Target expressed on lymphocytes and tumors offers unique advantages for unlocking the immune response to fight cancer.

Dietary Intervention Primes Triple-Negative Breast Cancer for Targeted Therapy

7/15/2015 11:03 am

(University of Wisconsin-Madison) July 14, 2015 - A diet that starves triple-negative breast cancer cells of an essential nutrient primes the cancer cells to be more easily killed by a targeted antibody treatment, UW Carbone Cancer Center scientists report in a recent publication.

Merck Extends Immuno-Oncology Collaboration with Agenus

6/3/2015 11:38 am

(MarketWatch) June 3, 2015 - Collaboration involves two proprietary Merck targets.

Agenus Announces Oral Presentation at ASCO Highlighting Improved Survival with Prophage Immunotherapy in Brain Cancer Compared to Historical Controls

5/14/2015 01:21 pm

(MarketWatch) May 14, 2015 - Agenus Inc., an immunology company developing innovative treatments for cancers and other diseases, today announced that data on continuing survival from a Phase 2 study of its Prophage vaccine in glioblastoma multiforme (GBM) has been selected for an oral presentation at the 2015 ASCO Annual Meeting, to be held May 29 – June 2, 2015 in Chicago.

Incyte, Agenus Launch Up-to-$410M-Plus Cancer Immunotherapy Collaboration

1/9/2015 11:33 am

(Genetic Engineering & Biotechnology News) Jan 9, 2015 - Incyte and Agenus said today they will develop and commercialize cancer immunotherapeutics by using the latter’s Retrocyte Display™ antibody discovery platform.

Mark Soloway, MD, Internationally Recognized Leader in Urologic Oncology, Joins Memorial Cancer Institute to Start New Division

7/18/2014 06:02 am

(PRWeb) July 17, 2014 - Dr. Mark Soloway, who has been appointed Chief of Urologic Oncology at Memorial Cancer Institute, will lead a new division focused on the care of bladder, prostate and kidney cancers, while also establishing a research program.

Promising Phase II Results for Agenus' Brain Cancer Vaccine

7/1/2014 11:25 am

(GEN) July 1, 2014 - The Phase II results are in for Agenus' autologous cancer vaccine Prophage: According to the immuno-oncology firm, the single-arm, multi-institutional, open-label study showed that patients with newly diagnosed glioblastoma multiforme (GBM) who received Prophage in addition to the standard of care treatment lived nearly twice as long as expected.

Agenus Brain Cancer Vaccine Nearly Doubles Survival Rate in Study

7/1/2014 06:54 am

(Reuters) July 1, 2014 - Agenus Inc said its experimental cancer vaccine helped brain tumor patients live nearly twice as long compared with those who received standard of care treatment.

Promising Phase II Results for Agenus' Brain Cancer Vaccine

7/1/2014 06:02 am

(GEN) July 1, 2014 - The Phase II results are in for Agenus' autologous cancer vaccine Prophage: According to the immuno-oncology firm, the single-arm, multi-institutional, open-label study showed that patients with newly diagnosed glioblastoma multiforme (GBM) who received Prophage in addition to the standard of care treatment lived nearly twice as long as expected.

Agenus Brain Cancer Vaccine Nearly Doubles Survival Rate in Study

7/1/2014 01:05 am

(Reuters) July 1, 2014 - Agenus Inc said its experimental cancer vaccine helped brain tumor patients live nearly twice as long compared with those who received standard of care treatment.

GTx Reports Positive Clinical Data from Open Label Phase 2 Study of Enobosarm in Patients with Androgen and Estrogen Receptor Positive Metastatic Breast Cancer

6/2/2014 01:03 pm

(GTx) June 2, 2014 - GTx, Inc. today announced positive results from a Phase 2, proof-of-concept, open-label clinical study evaluating enobosarm (GTx-024), a selective androgen receptor modulator (SARM), for the treatment of patients with androgen receptor (AR) positive and estrogen receptor (ER) positive metastatic breast cancer who have previously responded to hormonal therapy.

Agenus Announces Collaboration and License Agreement with Merck for Novel Checkpoint Antibody-Based Cancer Immunotherapies

4/28/2014 12:13 pm

(Yahoo! Finance) Apr 28, 2014 - Agenus Inc. announced today that the company has entered into a collaboration and license agreement with Merck for the discovery and development of therapeutic antibodies to immune checkpoints for the treatment of cancer.

Agenus Announces Collaboration and License Agreement with Merck for Novel Checkpoint Antibody-Based Cancer Immunotherapies

4/28/2014 12:01 pm

(Yahoo! Finance) Apr 28, 2014 - Agenus Inc. announced today that the company has entered into a collaboration and license agreement with Merck for the discovery and development of therapeutic antibodies to immune checkpoints for the treatment of cancer.

Investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic Does Not Meet First Co-Primary Endpoints in MAGRIT, a Phase III Non-Small Cell Lung Cancer Clinical Trial

3/20/2014 07:00 am

(GlaxoSmithKline) Mar 20, 2014 - GSK will continue the trial in order to assess the third co-primary endpoint, which is disease-free survival in a gene signature positive sub-population.

Agenus Completes Acquisition of 4-Antibody

2/13/2014 12:04 pm

(Yahoo! Finance) Feb 13, 2014 - Agenus Inc., a biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer vaccines and adjuvants, today completed the previously announced acquisition of 4-Antibody AG, a private European-based biopharmaceutical company.

Agenus Completes Acquisition of 4-Antibody

2/13/2014 12:00 pm

(Yahoo! Finance) Feb 13, 2014 - Agenus Inc., a biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer vaccines and adjuvants, today completed the previously announced acquisition of 4-Antibody AG, a private European-based biopharmaceutical company.

Agenus Announces Phase 2 Checkpoint inhibitor Combination Trial with Prophage Cancer Vaccine for Melanoma

1/14/2014 11:49 am

(MarketWatch) Jan 14, 2014 - Phase 2 randomized trial will study Yervoy® and Prophage combination for metastatic melanoma; first checkpoint inhibitor combination trial with Prophage vaccine.

Agenus Announces Phase 2 Checkpoint inhibitor Combination Trial with Prophage Cancer Vaccine for Melanoma

1/14/2014 11:04 am

(MarketWatch) Jan 14, 2014 - Phase 2 randomized trial will study Yervoy® and Prophage combination for metastatic melanoma; first checkpoint inhibitor combination trial with Prophage vaccine.

Agenus Enters into Definitive Agreement to Acquire Privately Held 4-Antibody AG

1/13/2014 11:05 am

(Yahoo! Finance UK) Jan 13, 2014 - 4-Antibody has a powerful platform for rapid discovery and optimization of fully-human antibodies against a wide array of molecular targets; lead programs target six immune checkpoint molecules; checkpoint antibodies have produced unprecedented results against a variety of cancers affecting a large number of patients; collaborations with the Ludwig Institute for Cancer Research and Memorial Sloan-Kettering Cancer Center.

Agenus Brain Cancer Vaccine Shows Promise in Study

12/16/2013 11:31 am

(Reuters) Dec 16, 2013 - Agenus Inc said more than 90 percent of patients treated with its experimental brain cancer vaccine were alive six months after undergoing surgery to remove the tumors.

Biomarker May Help Predict Aggressive Cancers

11/5/2013 11:04 am

(AACR) Nov 4, 2013 - For children with central nervous system cancers, the presence of a specific genetic modification—hypermethylation of the TERT promoter—may help predict tumor progression and patient survival, according to results presented at the AACR special conference on Pediatric Cancer at the Crossroads: Translating Discovery Into Improved Outcomes, held Nov. 3-6.

Agenus Brain Cancer Vaccine Improves Survival in Mid-Stage Study

9/17/2013 12:07 pm

(Reuters) Sep 17, 2013 - Biotechnology company Agenus Inc said its experimental brain cancer vaccine increased the survival of patients without their cancer worsening in a mid-stage trial, compared with the standard treatment.

Agenus Brain Cancer Vaccine Improves Survival in Mid-Stage Study

9/17/2013 12:00 pm

(Reuters) Sep 17, 2013 - Biotechnology company Agenus Inc said its experimental brain cancer vaccine increased the survival of patients without their cancer worsening in a mid-stage trial, compared with the standard treatment.

Agenus Plunges After Partner Glaxo Reports Drug Trial Failure

9/5/2013 12:54 pm

(BloombergBusinessweek) Sep 5, 2013 - Agenus Inc., a developer of treatments for cancer and infectious diseases, plummeted the most in four years after partner GlaxoSmithKline Plc’s MAGE-A3 vaccine failed to help skin-tumor patients in a trial.

Agenus Plunges After Partner Glaxo Reports Drug Trial Failure

9/5/2013 12:01 pm

(Bloomberg Businessweek) Sep 5, 2013 - Agenus Inc., a developer of treatments for cancer and infectious diseases, plummeted the most in four years after partner GlaxoSmithKline Plc’s (GSK) MAGE-A3 vaccine failed to help skin-tumor patients in a trial.

Agenus Begins Phase 2 Trials of Brain Tumor Vaccine

5/23/2013 12:21 pm

(Boston Business Journal) May 22, 2013 - Stock in Agenus Inc. rose more than 4 percent after the company announced it's started enrolling patients in what it says is the largest vaccine trial ever funded by the National Cancer Institute in brain tumors.

New York Tobacco Regulations Light Up Public Health Debate

5/2/2013 12:01 pm

(NPR) May 2, 2013 - If you're under 21, you may soon have a hard time lighting up in New York City. Public health officials in New York want to raise the minimum age for buying cigarettes.

Agenus Trial of Brain Cancer Vaccine Shows Better Survival Rate

5/2/2013 11:49 am

(Boston Business Journal) May 1, 2013 - Agenus Inc. on Wednesday reported results from a mid-stage trial of a potential brain cancer vaccine showing big increases in both progression-free and overall survival.

Agenus Trial of Brain Cancer Vaccine Shows Better Survival Rate

5/2/2013 11:04 am

(Boston Business Journal) May 1, 2013 - Agenus Inc. on Wednesday reported results from a mid-stage trial of a potential brain cancer vaccine showing big increases in both progression-free and overall survival.

Ziopharm in Partner Talks for Experimental Cancer Drug

2/13/2013 12:03 pm

(BloombergBusinessweek) Feb 12, 2013 - Ziopharm Oncology Inc, a developer of experimental cancer drugs, is in talks with potential partners to market its lead compound, palifosfamide, Chief Executive Officer Jonathan Lewis said.

Distress Screening for Cancer Patients

12/13/2012 11:05 am

(ACCC Buzz) Dec 10, 2012 - The American College of Surgeons Commission on Cancer’s new Standard 3.2: Psychosocial Distress Screening continues to be a hot topic of discussion. Even a recent Wall Street Journal column, “To Treat the Cancer, Treat the Distress,” took note of the new mandate.

Op-Ed Column: A Possibly Fatal Mistake

10/15/2012 12:01 pm

(New York Times) Oct 12, 2012 - For all his innate prudence, Scott now, at age 52, is suffering from Stage 4 prostate cancer, in part because he didn’t have health insurance. President Obama’s health care reform came just a bit too late to help Scott, but it will protect others like him — unless Mitt Romney repeals it.

FDA Considers Faster Approval Process for Obesity Drugs

10/12/2012 11:00 am

(Bloomberg Businessweek) Oct 11, 2012 - Obesity treatments, life-saving antibiotics and other drugs deemed to offer societal benefit despite their risks may get speedier U.S. approvals under plans being discussed to better balance innovation and safety.

Agenus to Join Russell 3000 Index, Global Index, and MicroCap Index

6/18/2012 01:05 pm

[GlobeNewswire] - LEXINGTON, Mass. -- Agenus, Inc. , a biotechnology company working to develop treatments for cancers and infectious diseases, today announced that it is set to join the broad-market Russell 3000(R) Index, ...

Injectable Boniva Drug in Short Supply - US FDA

6/7/2012 12:04 pm

(Reuters) June 7, 2012 - Patients who want an injectable form of Roche Holding AG's bone-strengthening drug Boniva may not be able to get it in the next few weeks because the company did not accurately forecast demand, federal officials said.

Agenus to Webcast 2012 Annual Shareholders Meeting

6/1/2012 04:01 pm

[GlobeNewswire] - LEXINGTON, Mass. -- Agenus Inc. invites investors and the general public to its 2012 Annual Shareholders Meeting at 5:00 p.m. ET on Wednesday, June 13th. The meeting will be held at the company's headquarters ...

AGENUS INC Financials

5/17/2012 05:00 pm